Total trials
134
Active
37
Phase 3
12
Total enrollment
39,465
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Melphalan or Melphalan + Topotecan | — | — | — | — | — | 1 | |
| etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy | — | — | — | — | — | 1 | |
| Carboplatin administered on Day 1 | — | — | — | — | — | 1 | |
| Intravitreal Melphalan chemotherapy injections | — | — | — | — | — | 1 | |
| Endocrine therapy | — | — | — | — | — | 1 | |
| Endocrine therapy combined with the local treatment of FES-negative lesions | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 2 | |
| Lenalidomide | — | — | — | — | — | 2 | |
| Tumor samples analysis | — | — | — | — | — | 1 | |
| Blood samples analysis: Circulating Tumor DNA | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Thiotepa | — | — | — | — | — | 1 | |
| Ibrutinib | — | — | — | — | — | 1 | |
| Tucatinib | — | — | — | — | — | 1 | |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | — | — | — | — | — | 1 | |
| VP16, carboplatin | — | — | — | — | — | 1 | |
| Melphalan | — | — | — | — | — | 1 | |
| VP16, carboplatin, vincristin | — | — | — | — | — | 1 | |
| Carboplatin + laser day 1 | — | — | — | — | — | 1 | |
| intravitreal Melphalan | — | — | — | — | — | 1 | |
| 68Ga-FAPI-46 for PET / CT scan | — | — | — | — | — | 1 | |
| Tucatinib in Combination of Oral VP16 and trastuzumab | — | — | — | — | — | 1 | |
| salivary kit | — | — | — | — | — | 1 | |
| assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria. | — | — | — | — | — | 1 |
Next readouts
- 2023-01
- 2026-08-15
- 2026-10-30
- 2027-06-06
- 2027-12-19
- 2028-12-07
- 2029-06-03
- 2029-08-04
- 2029-09-27
- 2031-03-01
Top conditions
- Breast Cancer18
- Cancer13
- Uveal Melanoma7
- Neuroblastoma5
- Triple Negative Breast Cancer5
- Cervical Cancer5
- Surgery4
- Solid Tumor, Adult4
Frequently asked questions about Institut Curie
- How many clinical trials does Institut Curie have on ClinicalTrials.gov?
- Institut Curie is listed as the lead sponsor on 134 clinical trials in ClinicalTrials.gov, 37 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institut Curie's trials are in Phase 3?
- 12 of Institut Curie's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does Institut Curie focus on?
- Institut Curie's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Uveal Melanoma, Neuroblastoma, Triple Negative Breast Cancer.
- When are Institut Curie's next clinical trial readouts?
- Institut Curie has 10 upcoming primary-completion readouts tracked here; the soonest is “Conservative Treatments of Retinoblastoma”, expected around 2023-01.